Navigation Links
At Six Months Post-Launch, Neurologist-Reported Patient Share for Tecfidera Among Relapsing-Remitting Multiple Sclerosis Patients Already Rivals that of Gilenya

EXTON, Pa., Dec. 10, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that neurologist-reported patient share for Biogen Idec's Tecfidera, the newest oral disease-modifying therapy (DMT) to reach the multiple sclerosis (MS) market, has increased significantly to seven percent among DMT-treated relapsing-remitting MS (RR-MS) patients, compared with one and three months post-launch. At six months post-launch, Tecfidera's patient share already matches that of Novartis's Gilenya, the first oral DMT (which became commercially available three years ago) and surpasses that of Genzyme's Aubagio, the second oral DMT, which launched one year ago. This growth in Tecfidera's patient share is driven by significant growth in volume per prescriber, reflecting widening adoption within individual practices, as well as significant expansion of the prescriber base (80 percent of surveyed neurologists). Patient origination data show a trend towards fewer patients initiating Tecfidera therapy following a treatment gap of two or more months, suggesting that most patients warehoused in anticipation of Tecfidera's launch have already been switched to the therapy at six months post-launch.

(Logo: )

The recently published LaunchTrends: Tecfidera (Wave 3) US 2013 report finds that one-fifth of Tecfidera-treated patients have experienced flushing and/or gastrointestinal events according to prescribers, significantly fewer than three months ago. This decrease is likely the result of increased physician and patient experience with the product, allowing for better management of potential side effects. However, tolerability issues continue to be the most common reason for Tecfidera discontinuation, as findings suggest that gastrointestinal events are more disruptive to treatment than flushing. Additionally, prescribers report that significantly more patients discontinued Tecfidera due to cost issues compared with three months ago. Neurologists continue to identify cost and managed care issues among the main obstacles to using Tecfidera more, potentially driven by the significant increase in Tecfidera prescription denials by managed care companies for treatment-naive and switched patients. During qualitative interviews, neurologists, while identifying treatment-naive patients among the most likely candidates for Tecfidera, often reported difficulty getting Tecfidera approved as a first-line agent.

"Even with potential access issues, uptake among current nonprescribers and continued use among prescribers will help drive significant growth in Tecfidera patient share to a forecasted 18 percent over the next six months,"  said BioTrends Research Group Senior Business Insights Analyst Emma Williams, Ph.D. "Together with the slight, yet significant, increase in patient shares for Aubagio and Gilenya, oral DMT share is expected to expand to one-third of the market, stealing share from the platform mainstays including Biogen Idec's Avonex, Bayer HealthCare's Betaseron, Teva's Copaxone, and Pfizer/EMD Serono's Rebif, signaling the evolution of the MS treatment algorithm away from injectable drugs."

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort

SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
2. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
3. New silk technology preserves heat-sensitive drugs for months without refrigeration
4. Verenium Reports Financial Results For The Second Quarter And Six Months Ended June 30, 2012
5. Origin Agritech Limited Reports Unaudited Third Quarter Financial Results For Three Months Ended June 30, 2012
6. Insmed Announces Financial Results For Second Quarter And Six-months Ended June 30, 2012
7. New technology delivers sustained release of drugs for up to 6 months
8. Cord Blood America Announces 3rd Quarter and Nine Months 2012 Financial Results
9. Origin Agritech Limited Reports Unaudited First Quarter Financial Results For Three Months Ended December 31, 2012
10. Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
11. China Cord Blood Corporation to Report Third Quarter and First Nine Months of Fiscal 2013 Financial Results
Post Your Comments:
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... Science Center’s FirstHand program has won a US2020 STEM Mentoring Award. Representatives of ... award for Excellence in Volunteer Experience from US2020. , US2020’s mission is to ...
(Date:10/10/2017)... SomaGenics announced the receipt of a Phase ... (Single Cell), expected to be the first commercially available ... from single cells using NGS methods. The NIH,s recent ... development of approaches to analyze the heterogeneity of cell ... for measuring levels of mRNAs in individual cells have ...
(Date:10/9/2017)... Oct. 9, 2017  BioTech Holdings announced today ... which its ProCell stem cell therapy prevents limb ... The Company, demonstrated that treatment with ProCell resulted ... saved as compared to standard bone marrow stem ... resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree Wellness ... targeting the needs of consumers who are incorporating medical marijuana into their wellness ... Arizona. , As operators of two successful Valley dispensaries, The Giving Tree’s two ...
Breaking Biology Technology:
(Date:3/27/2017)... 2017  Catholic Health Services (CHS) has been ... (HIMSS) Analytics for achieving Stage 6 on the ... In addition, CHS previously earned a place in ... electronic medical record (EMR). "HIMSS Analytics ... EMR usage in an outpatient setting.  This recognition ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
(Date:3/23/2017)... DUBLIN , Mar. 23, 2017 Research ... Anti-Theft System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 8.8% over the next ... This industry report analyzes the market estimates and forecasts for all ...
Breaking Biology News(10 mins):